Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia

Clinical Pharmacology and Therapeutics

Volumn 86, Issue 1, 2009, Pages 84-91

  Friberg, L E ^a   De Greef, R ^b   Kerbusch, T ^b   Karlsson, M O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASENAPINE; PLACEBO;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG WITHDRAWAL; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SIMULATION; STATISTICAL MODEL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; COMPUTER SIMULATION; CONTROLLED CLINICAL TRIALS AS TOPIC; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; MODELS, BIOLOGICAL; PATIENT DROPOUTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS;

EID: 67650608192     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.44     Document Type: Article

References (25)

1. Welge, J.A. & Keck, P.E. Jr. Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression. Psychopharmacology (Berl.) 166, 1-10 (2003).
2. Wahlbeck, K., Tuunainen, A., Ahokas, A. & Leucht, S. Dropout rates in randomized antipsychotic drug trials. Psychopharmacology (Berl.) 155, 230-233 (2001).
3. Mallinckrodt, C.H. et al. Assessing and interpreting treatment efects in longitudinal clinical trials with missing data. Biol. Psychiatry 53, 754-760 (2003).
4. Lane, P. Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. Pharm. Stat. 7, 93-106 (2007).
5. Shahid, M., Walker, G.B., Zorn, S.H. & Wong, E.H. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J. Psychopharmacol. 23, 65-73 (2009).
6. Frånberg, O. et al. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical efects in schizophrenia. Psychopharmacology (Berl.) 196, 417-429 (2008).
7. Potkin, S.G., Cohen, M. & Panagides, J. Efcacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J. Clin. Psychiatry 68, 1492-1500 (2007).
8. Potkin, S.G., Kane, J.M., Emsley, R.A., Naber, D. & Panagides, J. Asenapine in schizophrenia: an overview of clinical trials in the Olympia Program. 1st Schizophrenia International Research Society Conference, Venice, Italy, 21-25 June 2008.
9. Kane, J.M., Zhao, J., Cohen, M. & Panagides, J. Efcacy and safety of asenapine in patients with acute schizophrenia. New Clinical Drug Evaluation Unit 48th Annual Meeting, Phoenix, AZ, 27-30 May 2008.
10. Szegedi, A. et al. Placebo response in antipsychotic clinical trials: overview of the literature and case examples. New Clinical Drug Evaluation Unit 48th Annual Meeting, Phoenix, AZ, 27-30 May 2008.
11. Geddes, J., Freemantle, N., Harrison, P. & Bebbington, P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321, 1371-1376 (2000).
12. Sheiner, L.B. & Steimer, J.L. Pharmacokinetic/pharmacodynamic modeling in drug development. Annu. Rev. Pharmacol. Toxicol. 40, 67-95 (2000).
13. Jonsson, E.N. & Sheiner, L.B. More efcient clinical trials through use of scientifc model-based statistical tests. Clin. Pharmacol. Ther. 72, 603-614 (2002).
14. Lalonde, R.L. et al. Model-based drug development. Clin. Pharmacol. Ther. 82, 21-32 (2007).
15. Kimko, H.C., Reele, S.S., Holford, N.H. & Peck, C.C. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. Clin. Pharmacol. Ther. 68, 568-577 (2000).
16. Karlsson, M.O. & Savic, R.M. Diagnosing model diagnostics. Clin. Pharmacol. Ther. 82, 17-20 (2007).
17. Mauri, M.C., Volonteri, L.S., Colasanti, A., Fiorentini, A., De Gaspari, I.F. & Bareggi, S.R. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin. Pharmacokinet. 46, 359-388 (2007).
18. Ortega, I., Vermeulen, A. & Piotrovsky, V. Concentration-response analysis of antipsychotic drug efects using an indirect response model. PAGE 15, Bruges, Belgium, 2006. Abstr 995. .
19. Mallinckrodt, C.H., Clark, W.S. & David, S.R. Accounting for dropout bias using mixed-efects models. J. Biopharm. Stat. 11, 9-21 (2001).
20. Hu, C. & Sale, M.E. A joint model for nonlinear longitudinal data with informative dropout. J. Pharmacokinet. Pharmacodyn. 30, 83-103 (2003).
21. Kemp, A.S. et al. What is causing the reduced drug-placebo diference in recent schizophrenia trials and what can be done about it? Schizophr. Bull. (2008); e-pub ahead of print 22 August 2008.
22. Beal, S.L., Sheiner, L.B. & Boeckmann, A.J. NONMEM Users Guides (Icon Development Solutions, Ellicott City, MD, 1989-2006).
23. Jonsson, E.N. & Karlsson, M.O. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58, 51-64 (1999).
24. Lindbom, L., Pihlgren, P. & Jonsson, E.N. PsN-Toolkit - a collection of computer intensive statistical methods for non-linear mixed efect modeling using NONMEM. Comput. Methods Programs Biomed. 79, 241-257 (2005).
25. Wilkins, J.J., Karlsson, M.O. & Jonsson, E.N. Patterns and power for the visual predictive check. PAGE 15, Bruges, Belgium, 2006. Abstr 1029. .